ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher ...

On January 29, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the grant of a preliminary injunction by the Northern District of ...

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

Genomics is bringing in a new wave of money from an unlikely group of investors — health systems. More providers are ...

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

Ultragenyx Pharmaceutical RARE reported fourth-quarter 2024 loss of $1.39 per share, wider than the Zacks Consensus Estimate ...

Scientists have uncovered a strong link between zinc levels in the human body and the risk of developing type 2 diabetes and non-alcoholic fatty liver disease. Their findings highlight the importance ...

The stock's rise snapped a four-day losing streak.

Any registered Democrat living in the Village of New Paltz who is interested in seeking the role is invited to contact [email protected] and submit a letter of interest and cover letter. Letters ...